Compare Marqeta Inc (MQ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Sanofi SA — how do they compare? Marqeta Inc trades at $18.11 (market cap $1.82B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 52.3× Marqeta Inc's market cap, and Sanofi SA pays a 6.01% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Sanofi SA for 94 Days on average.
| MQ | SNY | |
|---|---|---|
Market Cap | $1.82B | $95.18B |
Volume | 1,126,466 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $20.32 | $52.34 |
52-Week Low | $15.04 | $39.51 |
Typical Hold Time | 44 Days | 94 Days |
Enterprise Value | $1.13B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MQ trades at $17.44, up 2.23% today, with a bullish technical signal from moving averages. The company reported three consecutive quarterly EPS beats, with Q3 2026 results due November 3. Revenue grew to $625M in 2025, but net income was negative. Analyst consensus is mixed, with 32% buy ratings but a price target of $11.38, below the current price. Recent news includes partnerships with BVNK for stablecoin cards and Google for wallet expansions.
MQ shows operational improvement with positive cash flow in 2025, but high valuation ratios and thin margins pose risks. The stock faces headwinds from contract renewals in Q3 2026, which may slow growth. Upside depends on sustained earnings beats and successful product expansions. Investors should weigh the bullish technicals against fundamental challenges and analyst caution.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
